Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($2.10), $0.16 better than the analyst estimate of ($2.26). Revenue for the quarter came in at $97 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.